WALTHAM, Mass., Nov. 21, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...

Upstream Bio, Inc. ( (UPB) ) has released its Q3 earnings. Here is a breakdown of the information Upstream Bio, Inc. presented to its ...

Upstream Bio’s (NASDAQ:UPB – Get Free Report) quiet period is set to end on Wednesday, November 20th. Upstream Bio had issued 15,000,000 shares in its initial public offering on October 11th.

Early preclinical and clinical data for verekitug indicate a potential for even greater efficacy than Tezspire. Upstream Bio ...

Upstream Bio, Inc. ( (UPB)) has released its Q3 earnings. Here is a breakdown of the information Upstream Bio, Inc. presented to its investors. Upstream Bio, Inc., a clinical-stage biotechnology ...

On Tuesday, Upstream Bio (NASDAQ:UPB) received a positive outlook from TD Cowen, as the firm started coverage on the biotech company's stock with a Buy rating. The optimism is based on the ...

Nov. 07, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders, ...

Nov. 07, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe respiratory disorders ...

Piper Sandler began coverage on shares of Upstream Bio (NASDAQ:UPB – Free Report) in a research report released on Tuesday morning, MarketBeat.com reports. The firm issued an overweight rating ...

WALTHAM, Mass., Nov. 07, 2024 (GLOBE NEWSWIRE) -- Upstream Bio, Inc. (Nasdaq: UPB), a clinical-stage company developing treatments for inflammatory diseases, with an initial focus on severe ...